Louisiana State Employees Retirement System Acquires New Position in Globus Medical, Inc. $GMED

Louisiana State Employees Retirement System purchased a new position in shares of Globus Medical, Inc. (NYSE:GMED) during the first quarter, Holdings Channel.com reports. The fund purchased 32,300 shares of the medical device company’s stock, valued at approximately $2,783,000.

Several other hedge funds have also made changes to their positions in GMED. Invesco Ltd. lifted its stake in Globus Medical by 1,235.2% in the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after buying an additional 3,595,339 shares during the last quarter. Bank of Montreal Can increased its holdings in shares of Globus Medical by 15,317.1% in the 4th quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after acquiring an additional 3,351,380 shares during the period. William Blair Investment Management LLC lifted its position in Globus Medical by 17.2% in the 3rd quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock valued at $161,454,000 after purchasing an additional 414,134 shares during the last quarter. Sculptor Capital LP boosted its stake in Globus Medical by 31.9% during the 2nd quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after purchasing an additional 667,850 shares during the period. Finally, Madison Avenue Partners LP grew its position in Globus Medical by 3.0% in the 4th quarter. Madison Avenue Partners LP now owns 2,624,751 shares of the medical device company’s stock worth $229,167,000 after purchasing an additional 76,588 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Royal Bank Of Canada lifted their price target on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Wells Fargo & Company decreased their price target on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Needham & Company LLC raised their price target on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $105.00.

Globus Medical Stock Down 0.2%

Shares of NYSE GMED opened at $86.05 on Monday. The stock’s fifty day simple moving average is $83.58 and its 200 day simple moving average is $87.40. The stock has a market capitalization of $11.68 billion, a price-to-earnings ratio of 20.01, a PEG ratio of 1.78 and a beta of 0.95. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. During the same period last year, the firm posted $0.68 earnings per share. The firm’s quarterly revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, analysts anticipate that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Insider Transactions at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 18.38% of the stock is currently owned by insiders.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.